The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Lonza plans to invest approximately CHF 500 million to upgrade the facility
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Subscribe To Our Newsletter & Stay Updated
